Patents by Inventor Yelena Bisharyan

Yelena Bisharyan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11597763
    Abstract: Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: March 7, 2023
    Assignee: Tetragenetics, Inc.
    Inventors: Paul A. Colussi, Janna Bednenko, Yelena Bisharyan, Ashot Papoyan, Joanna Cardarelli, Theodore G. Clark, Douglas Kahn, Lore Mariën, Bas Van Der Woning, Hans De Haard, William D. Harriman, Ellen J. Collarini, Alka Agrawal
  • Publication number: 20190144538
    Abstract: Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.
    Type: Application
    Filed: May 2, 2017
    Publication date: May 16, 2019
    Applicant: Tetragenetics, Inc.
    Inventors: Paul A. Colussi, Janna Bednenko, Yelena Bisharyan, Ashot Papoyan, Joanna Cardarelli, Theodore G. Clark, Douglas Kahn, Lore Mariën, Bas Van Der Woning, Hans De Haard, William D. Harriman, Ellen J. Collarini
  • Publication number: 20170089921
    Abstract: Methods are disclosed for the production of mammalian voltage-gated ion channels in ciliates. In other aspects, compositions comprising lipid bilayers containing mammalian voltage-gated ion channels are disclosed. In other aspects, compositions comprising purified and reconstituted mammalian voltage-gated ion channels are disclosed.
    Type: Application
    Filed: May 5, 2015
    Publication date: March 30, 2017
    Inventors: Paul COLUSSI, Ashot PAPOYAN, Yelena BISHARYAN, Janna BEDNENKO, Theodore G. CLARK
  • Patent number: 9512181
    Abstract: This invention is directed to methods for the production of immunogenic granular particles. In certain embodiments, the invention is directed to methods and products for the production of immunogenic granular particles produced in ciliates. In certain embodiments, the invention is directed to compositions comprising Granule lattice protein/Antigen(Grl/Ag) fusion polypeptides.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: December 6, 2016
    Assignee: Tetragenetics, Inc.
    Inventors: Theodore G. Clark, Yelena Bisharyan, Ashot Papoyan, Kyle Anderson, Paul Colussi
  • Publication number: 20150125483
    Abstract: This invention is directed to methods for the production of immunogenic granular particles. In certain embodiments, the invention is directed to methods and products for the production immunogenic granular particles produced in ciliates. In certain embodiments, the invention is directed to compositions comprising Grl/Ag fusion polypeptides.
    Type: Application
    Filed: May 29, 2012
    Publication date: May 7, 2015
    Applicant: Tetragenetics, Inc.
    Inventors: Theodore G. Clark, Yelena Bisharyan, Ashot Papoyan, Kyle Anderson, Paul Colussi